

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





JAK2 V617F Mutation Analysis - Qualitative

Alternative Name

JAK2 Mutation Analysis

Methodology

Molecular

Test Description

Qualitative detection of the V617F mutation. The rare mutation V617I is also detected. Testing is performed on plasma for increased sensitivity whenever possible. V617F testing may be ordered separately, concurrently with full exon 12-13 sequencing, with reflex to exon 12-13 sequencing, or as part of the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL. Testing is approved for specimens from the state of New York.

Clinical Significance

The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately 40% of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Mutation analysis helps differentiate reactive conditions from myeloproliferative neoplasms (MPNs).

Specimen Requirements

Peripheral Blood: 5 mL EDTA tube
Bone Marrow: 2 mL EDTA tube

Note: Test is RNA-based. Please select **Extract & Hold – RNA** if specimen hold service is desired. If considering the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL test as an add-on, we recommend adding Extract & Hold – DNA with Extract & Hold – RNA order.

Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.

CPT Code(s)*

81270

New York Approved

Yes

Level of Service

Global

Turnaround Time

7 days



NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912

Phone: 239.768.0600/ Fax: 239.690.4237

neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners

Rev. 112124